NASDAQ:VIVE Viveve Medical (VIVE) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free VIVE Stock Alerts $0.0002 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.00▼$0.11Volume11,567 shsAverage Volume3,451 shsMarket Capitalization$2,144.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsSEC FilingsSocial Media Get Viveve Medical alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Viveve Medical Stock (NASDAQ:VIVE)Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.Read More VIVE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIVE Stock News HeadlinesApril 17, 2024 | finance.yahoo.com5-Alpha Reductase Deficiency Global Market Report 2024: A $1.94 Billion Projected Market in 2028April 15, 2024 | finance.yahoo.comInMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTLApril 27, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.February 23, 2024 | benzinga.comViveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, PredictionsJuly 29, 2023 | seekingalpha.comVIVE Viveve Medical, Inc.July 25, 2023 | finance.yahoo.comInMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve PatentsJune 14, 2023 | uk.finance.yahoo.comVIVE - Viveve Medical, Inc.February 24, 2023 | finance.yahoo.comViveve Medical, Inc. (VIVE)April 27, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.January 17, 2023 | msn.comWhy Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionJanuary 17, 2023 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceJanuary 17, 2023 | seekingalpha.comViveve crashes ~60% as company decides to delist, explore sale after trial failsJanuary 17, 2023 | finance.yahoo.comViveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceJanuary 17, 2023 | finance.yahoo.comViveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence TrialJanuary 17, 2023 | investorplace.comWhy Is Viveve Medical (VIVE) Stock Down 69% Today?December 29, 2022 | insidermonkey.comViveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call TranscriptDecember 15, 2022 | finance.yahoo.comViveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits ConcludedDecember 1, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceDecember 1, 2022 | finance.yahoo.comViveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceNovember 13, 2022 | finance.yahoo.comViveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 10, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comViveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 27, 2022 | finance.yahoo.comViveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022October 25, 2022 | finance.yahoo.comGlobal Cosmetic Gynecology Market Report to 2027 - Featuring Alma Laser, Lutronic, Viveve Medical and Venus Concept Among OthersOctober 13, 2022 | forbes.comViveve MedicalOctober 4, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceOctober 4, 2022 | finance.yahoo.comViveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceSee More Headlines Receive VIVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viveve Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:VIVE Previous SymbolOTCMKTS:PLCSD CUSIPN/A CIK879682 Webwww.viveve.com Phone(720) 696-8100Fax720-696-8199Employees47Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares10,720,000Free Float10,110,000Market Cap$2,144.00 OptionableNot Optionable Beta0.08 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Jim B. Robbins (Age 60)Senior VP of Finance & Administration and Principal Accounting & Financial Officer Comp: $386.94kMs. Deborah Ann Jorn M.B.A. (Age 66)Senior Advisor to the CEO & Director Comp: $35kMr. Martin Kerber P.E.Vice President of Research, Development & OperationsMs. Jeannie SwindleSenior Director of Corporate CommunicationsMr. Jeff SinclairVice President of International SalesMr. Gary KaiserVice President of Global MarketingMs. Lori McMillanVice President of Human ResourcesMs. Suzon D. Lommel (Age 66)Senior Vice President of Regulatory & Quality Affairs More ExecutivesKey CompetitorsKaleido BiosciencesNASDAQ:KLDOOncoSec MedicalNASDAQ:ONCSQGenocea BiosciencesNASDAQ:GNCAHTG Molecular DiagnosticsNASDAQ:HTGMQViewRayNASDAQ:VRAYQView All Competitors VIVE Stock Analysis - Frequently Asked Questions How have VIVE shares performed in 2024? Viveve Medical's stock was trading at $0.0002 on January 1st, 2024. Since then, VIVE stock has increased by 0.0% and is now trading at $0.0002. View the best growth stocks for 2024 here. How were Viveve Medical's earnings last quarter? Viveve Medical, Inc. (NASDAQ:VIVE) issued its earnings results on Thursday, November, 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.09. The business earned $1.62 million during the quarter. During the same quarter last year, the company earned ($2.60) earnings per share. What other stocks do shareholders of Viveve Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), SCYNEXIS (SCYX), Western Digital (WDC), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Novavax (NVAX). When did Viveve Medical IPO? Viveve Medical (VIVE) raised $13 million in an initial public offering on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group served as the underwriters for the IPO and Maxim Group was co-manager. How do I buy shares of Viveve Medical? Shares of VIVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIVE) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viveve Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.